BioLineRx (NASDAQ:BLRX) today announced its audited financial results for the full year ended December 31, 2025, detailing a period of significant fiscal discipline and pipeline maturation.
The company reported a dramatically narrowed net loss of $2 million for 2025, compared to $9.2 million in 2024, reflecting a lean operational model as it maximizes the commercial potential of its lead asset while advancing a focused oncology pipeline.
The company's balance sheet remains stable with $20.9 million in cash and cash equivalents.
Management confirmed this provides a sufficient operational runway into the first half of 2027, covering several high-value clinical catalysts.
Additionally, BioLineRx received a Notice of Allowance from the USPTO for a patent covering GLIX1, its investigational agent for solid tumors.
This new intellectual property protection extends into 2040, with the potential for further regulatory extensions, providing a long-term commercial moat for the program.
Elsewhere, clinical momentum is expected to accelerate in the coming weeks.
BioLineRx is on track to initiate a Phase 1/2a trial for GLIX1 in patients with glioblastoma by the end of March 2026.
This study addresses one of the most aggressive and difficult-to-treat forms of brain cancer, with initial Phase 1 data targeted for release in the first half of 2027.
Concurrently, the company is advancing motixafortide, its approved stem cell mobilization agent, into broader oncology indications.
An interim analysis for the Chemo4METPANC Phase 2 trial in metastatic pancreatic ductal adenocarcinoma (mPDAC) is anticipated later in 2026.